13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
76 檔
23.9%
As reported in its official Q4 2025 Form 13F filing, Vestal Point Capital, LP's tracked investment portfolio stood at $4.3B with 76 total positions.
Vestal Point Capital, LP executed strategic sector rebalancing during Q4 2025, establishing 25 new positions while fully exiting 30 holdings and trimming 20 positions.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, QQQ, ACLXGBX) accounted for 23.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
QQQ
市值: $215.0M
Top Position Liquidated / Trimmed
AM6
前期市值: $76.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 8.71% | +2.65% | +90.00% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 7.31% | — | — | |
| 3 | ACLXGBX | Arcellx Inc | Stock-Other | 6.48% | — | +134.00% | |
| 4 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 6.18% | -1.47% | EXIT | |
| 5 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 6.06% | +2.41% | +261.45% | |
| 6 | GMED | Globus Medical Inc - A | Stock-Healthcare | 3.78% | +0.10% | +2.00% | |
| 7 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.02% | +1.74% | +34.96% | |
| 8 | ALC | Alcon Inc. | Stock-Healthcare | 2.96% | -0.91% | +0.45% | |
| 9 | DXCM | Dexcom Inc | Stock-Healthcare | 2.88% | — | +96.15% | |
| 10 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.77% | — | — | |
| 11 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.57% | +0.84% | +150.00% | |
| 12 | ABT | Abbott Laboratories | Stock-Healthcare | 2.56% | +2.97% | NEW | |
| 13 | ✓ | Immatics NV | Stock-Other | 2.19% | -0.24% | -3.54% | |
| 14 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.17% | -0.06% | EXIT | |
| 15 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.05% | +0.62% | -29.90% | |
| 16 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.03% | -0.99% | — | |
| 17 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.01% | +1.18% | +230.17% | |
| 18 | IRON | Disc Medicine Inc | Stock-Other | 1.98% | +1.40% | +47.00% | |
| 19 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.68% | — | -42.00% | |
| 20 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.65% | — | +94.39% | |
| 21 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.51% | -0.25% | +37.69% | |
| 22 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.50% | -0.82% | +161.58% | |
| 23 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.41% | -2.59% | EXIT | |
| 24 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.40% | -0.06% | — | |
| 25 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.30% | — | +40.00% | |
| 26 | ASND | Ascendis Pharma A/S | Stock-Other | 1.27% | -2.40% | EXIT | |
| 27 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.14% | -0.55% | +16.84% | |
| 28 | SLDB | Solid Biosciences Inc | Stock-Other | 1.12% | -0.51% | +95.46% | |
| 29 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.08% | -1.09% | EXIT | |
| 30 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.05% | -1.82% | EXIT | |
| 31 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.04% | -1.04% | EXIT | |
| 32 | VERA | Vera Therapeutics Inc | Stock-Other | 0.95% | -1.54% | EXIT | |
| 33 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.91% | -0.05% | -45.45% | |
| 34 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.81% | — | +111.76% | |
| 35 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.80% | -4.49% | -53.17% | |
| 36 | ZYME | Zymeworks Inc | Stock-Other | 0.77% | — | -50.99% | |
| 37 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.69% | -0.99% | — | |
| 38 | UPB | Upstream Bio Inc | Stock-Other | 0.66% | — | — | |
| 39 | BBNX | Beta Bionics Inc | Stock-Other | 0.62% | -0.03% | — | |
| 40 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.60% | -0.08% | — | |
| 41 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.60% | +0.07% | — | |
| 42 | PEN | Penumbra Inc | Stock-Healthcare | 0.53% | — | — | |
| 43 | GERN | Geron CORP | Stock-Other | 0.51% | -0.11% | EXIT | |
| 44 | RGEN | Repligen CORP | Stock-Healthcare | 0.46% | -1.77% | -79.25% | |
| 45 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.46% | +2.34% | — | |
| 46 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.46% | -0.62% | — | |
| 47 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.41% | +0.94% | -3.13% | |
| 48 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.37% | -0.24% | EXIT | |
| 49 | SVRA | Savara Inc | Stock-Other | 0.33% | -0.01% | -60.00% | |
| 50 | ✓ | Engene Holdings Inc | Stock-Other | 0.32% | -0.41% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +4.9% | +90.00% | Add |
| 2 | BMRN | Biomarin Pharmaceutical Inc | +4% | +261.45% | Add |
| 3 | ACLXGBX | Arcellx Inc | +1.9% | +134.00% | Add |
| 4 | TSHA | Taysha Gene Therapies Inc | +1.8% | +150.00% | Add |
| 5 | NRIX | Nurix Therapeutics Inc | +1.6% | +34.96% | Add |
| 6 | ANRO | Alto Neuroscience Inc | +1.3% | +161.58% | Add |
| 7 | ABT | Abbott Laboratories | +1.1% | +140.00% | Add |
| 8 | ELVN | Enliven Therapeutics Inc | +0.9% | +230.17% | Add |
| 9 | DXCM | Dexcom Inc | +0.9% | +96.15% | Add |
| 10 | DAWNGBX | Day One Biopharmaceuticals I | +0.8% | +94.39% | Add |
| 11 | APGE | Apogee Therapeutics Inc | +0.7% | +29.41% | Add |
| 12 | TYRA | Tyra Biosciences Inc | +0.6% | — | Unchanged |
| 13 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.6% | +152.00% | Add |
| 14 | GMED | Globus Medical Inc - A | +0.6% | +2.00% | Add |
| 15 | LXEO | Lexeo Therapeutics Inc | +0.5% | +37.69% | Add |
| 16 | IRON | Disc Medicine Inc | +0.5% | +47.00% | Add |
| 17 | AXSM | Axsome Therapeutics Inc | +0.5% | +40.00% | Add |
| 18 | LNTH | Lantheus Holdings Inc | +0.4% | +111.76% | Add |
| 19 | SLDB | Solid Biosciences Inc | +0.3% | +95.46% | Add |
| 20 | ✓ | Engene Holdings Inc | +0.2% | +185.14% | Add |
| 21 | GLUE | Monte Rosa Therapeutics Inc | +0.1% | -3.13% | Trim |
| 22 | BBNX | Beta Bionics Inc | +0.1% | — | Unchanged |
| 23 | AGIO | Agios Pharmaceuticals Inc | +0.1% | +155.91% | Add |
| 24 | MYGN | Myriad Genetics Inc | +0.1% | +103.83% | Add |
| 25 | PASG | Passage Bio Inc | 0% | — | Unchanged |
| 26 | NVCR | NovoCure Limited | — | +31.25% | Add |
| 27 | TENX | Tenax Therapeutics Inc | — | — | Unchanged |
| 28 | MGNX | Macrogenics Inc | — | — | Unchanged |
| 29 | OKUR | Onkure Therapeutics Inc-a | 0% | — | Unchanged |
| 30 | VERA | Vera Therapeutics Inc | -0.1% | -27.63% | Trim |
| 31 | ✓ | Nyxoah S A | -0.1% | -0.04% | Trim |
| 32 | FATE | Fate Therapeutics Inc | -0.1% | -31.41% | Trim |
| 33 | ALEC | Alector Inc | -0.1% | -22.96% | Trim |
| 34 | VYGR | Voyager Therapeutics Inc | -0.1% | — | Unchanged |
| 35 | RAPP | Rapport Therapeutics Inc | -0.1% | +16.84% | Add |
| 36 | ✓ | Immatics NV | -0.3% | -3.54% | Trim |
| 37 | SVRA | Savara Inc | -0.3% | -60.00% | Trim |
| 38 | CLDX | Celldex Therapeutics Inc | -0.3% | -3.32% | Trim |
| 39 | RVMD | Revolution Medicines Inc | -0.5% | -53.17% | Trim |
| 40 | GERN | Geron CORP | -0.6% | -34.28% | Trim |
| 41 | ZYME | Zymeworks Inc | -0.6% | -50.99% | Trim |
| 42 | ALC | Alcon Inc. | -0.7% | +0.45% | Add |
| 43 | BDTX | Black Diamond Therapeutics I | -0.9% | -84.32% | Trim |
| 44 | XENE | Xenon Pharmaceuticals Inc | -1.1% | -45.45% | Trim |
| 45 | JAZZ | Jazz Pharmaceuticals plc | -1.3% | -42.00% | Trim |
| 46 | SRRK | Scholar Rock Holding CORP | -1.5% | -53.33% | Trim |
| 47 | DYN | Dyne Therapeutics Inc | -1.5% | -95.68% | Trim |
| 48 | BCAX | Bicara Therapeutics Inc | -1.6% | -29.90% | Trim |
| 49 | RGEN | Repligen CORP | -2% | -79.25% | Trim |
| 50 | ASND | Ascendis Pharma A/S | -4.1% | -70.83% | Trim |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 76 disclosed positions in Q4 2025.
During Q4 2025, Vestal Point Capital, LP's top holdings by market value included ABVX (8.7%)、QQQ (7.3%)、ACLXGBX (6.5%). The largest single position, ABVX, represented 8.7% of total portfolio value.
In Q4 2025, Vestal Point Capital, LP made 99 total portfolio adjustments, initiating 25 new buys, adding to 24 positions, trimming 20 holdings, and fully liquidating 30 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.